References
- Gladstone DE, Bolaños-Meade J, Huff CA, . High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma 2011;52: In press.
- Tam CS, Bassett R, Ledesma C, . Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:4144–4152.
- Geisler CH, Kolstad A, Laurell A, . Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
- Salles G, Seymour JF, Offner F, . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011;377:42–51.
- Herman SEM, Gordon AL, Wagner AJ, . The phosphatidylinositol 3-kinase-delta inhibitor CAL-101 demonstrates promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078–2088.
- Burger JA, O'Brien S, Fowler N, . The Bruton's tyrosine kinase inhibitor PCI-32675 is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies. Blood 2010;116(Suppl. 1): Abstract 57.